Cabaletta Bio (NASDAQ:CABA) executives told investors at the Guggenheim Emerging Outlook Biotech Summit 2026 that the company has initiated enrollment in what it described as its first pivotal program ...

PHILADELPHIA--(BUSINESS WIRE)--Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B ...

About Cabaletta Bio Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for ...

Cabaletta didn't have any major announcements or any Securities and Exchange Commission (SEC) filings to make the stock rise. However, Guggenheim initiated coverage of the stock, with a price target ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...

--Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases ...

Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission - including an outpatient dosing option using a single weight-based dose IND amendment ...

– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in ...

Cabaletta Bio (CABA) has attracted fresh attention after presenting early data from its RESET-PV clinical trial at the ESGCT Congress. The company reported that its CAR T cell therapy, rese-cel, ...

The MarketWatch News Department was not involved in the creation of this content. -- All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational ...

– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling – – Additional clinical data ...